Advertisement
YOU ARE HERE: LAT HomeCollectionsPlays

In Search of a Play of One's Own

PERSPECTIVE

Under Gordon Davidson, the Taper's only true successes this season have originated elsewhere. It's time for some home-grown excellence.

December 31, 2000|MICHAEL PHILLIPS | Michael Phillips is The Times' theater critic

This isn't a crisis story. It's about matters more ambiguous: perception, image and that elusive commodity, reputation.

We are midway through the Mark Taper Forum's 2000-01 season. There's something epic in the very sound of that phrase--"2000-01 season," like a ship's prow braving unknown waters.

Epics come in various sizes. Two of the best-realized productions seen this year at the Taper, or anywhere in Los Angeles, were Mary Zimmerman's "Metamorphoses," modestly scaled and quietly enveloping, and August Wilson's "Jitney," minor doings from a major playwright but wonderfully enacted.

They were Taper shows, though "bookings" might be closer to the mark. They came from elsewhere, they conquered and then they left.

And they left the Taper's certifiably local work looking pretty pale by comparison. When a job-in such as "Metamorphoses," however elegant, scoops up a lion's share of kudos, there's a bittersweetness involved. I loved it. But it was Taper-hosted, not Taper-produced.

"Metamorphoses," a series of fantastical myths by Ovid retold for the stage, enjoyed success before L.A. in Chicago, Seattle and Berkeley. "Jitney"--not Wilson's first full-length play, as everyone seemed intent on reporting--played several cities in several productions in recent years. The version at the Taper (directed by Marion McClinton, who staged Wilson's newest work, "King Hedley II," also at the Taper) was somewhat revised by Wilson, as part of a de facto Taper-to-off-Broadway tryout. "Jitney" closes in New York on Jan. 28.

Such projects--imports, exports, import-exports, co-productions of all kinds--have become the rule, not the exception, at many nonprofits nationwide. Many people, including Taper artistic director Gordon Davidson, might argue: Why not? An adventurous show's point of origin or a commercially minded project's New York prospects matter a lot less when the work is worth seeing. And if the show in question is heading toward Manhattan and there's a percentage to be had, all the better. Case in point: Neil Simon's "The Dinner Party," now a financial success on Broadway.

No one's arguing the importance of finances. Job-ins, co-productions and New York hopefuls act as ports in a storm. They make a lot of sense on paper. Davidson is famously enthusiastic in his multiple roles as booker, broker, frontman, middleman, artist and administrator. Deals are simply the deal these days, in this time--a long time indeed--of paltry federal subsidy from the National Endowment for the Arts.

It's a time of increasingly fluid borders separating the commercial world from the not-for-profit world. (Naming rights for this article, in fact, are available for purchase--the Bed Bath & Beyond Commentary, perhaps.) It's a time in which a big-name mediocrity, such as "The Dinner Party," can try out under a nonprofit banner before moving on to tryout No. 2 at another nonprofit house (the Kennedy Center in Washington, D.C.) before scoring a solid commercial success on Broadway.

This is what we see at the Taper and elsewhere, increasingly, at one major regional house after another, in the name of survival and nonprofit-commercial "synergy."

*

The Taper is the acknowledged flagship of the big L.A. nonprofit stages. It is a primary player nationally. Yet this year, especially, the Taper seemed like a two-tier operation--two different theaters internally at odds. One Taper lent its name, resources and reputation to projects born or heading elsewhere. The other Taper went about its business, rather routinely.

Last year at the Taper, there were the "big," "outside" projects--"The Dinner Party" (which opened in December 1999) and the August Wilson plays chief among them. On the same stage, struggling for attention, were the "other" shows, including a world premiere by L.A.'s Robert Glaudini, "The Poison Tree." A disappointment, and worse, it was a play by someone with far more interesting material in his desk drawer.

Taper producing director Robert Egan sponsored that project, then undercut it with an uncertain staging. More recently, Egan staged the regional premiere of Patrick Marber's "Closer," hampered by the not-quite-star casting of Rebecca De Mornay. (Similarly, "The Poison Tree" starred Anne Archer, game but indistinct.) Both productions felt like work not quite up to big-league standard. Directorial competence isn't the same thing as excellence.

I'm not sure either script really belonged on the Taper stage to begin with. Glaudini's better works warrant Taper support, however, especially on a second stage, if the Taper actually had one. Ten years ago, people were complaining about the Taper's lack of a second stage. It is now the 21st century. We aren't talking about that many millions of dollars. Without an active and risk-prone second stage, a theater has no artistic safety valve. No safety valve, and you start sensing the economic pressure affecting every main stage effort.

Advertisement
Los Angeles Times Articles
|
|
|